- Home
- SOPH vs CHRS Comparison
SOPH vs CHRS Comparison
Compare SOPH & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOPH
- CHRS
- Stock Information
- Founded
- SOPH 2011
- CHRS 2010
- Country
- SOPH Switzerland
- CHRS United States
- Employees
- SOPH N/A
- CHRS N/A
- Industry
- SOPH Biotechnology: Biological Products (No Diagnostic Substances)
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SOPH Health Care
- CHRS Health Care
- Exchange
- SOPH Nasdaq
- CHRS Nasdaq
- Market Cap
- SOPH 231.8M
- CHRS 186.0M
- IPO Year
- SOPH 2021
- CHRS 2014
- Fundamental
- Price
- SOPH $4.52
- CHRS $1.57
- Analyst Decision
- SOPH
- CHRS Strong Buy
- Analyst Count
- SOPH 0
- CHRS 4
- Target Price
- SOPH N/A
- CHRS $4.51
- AVG Volume (30 Days)
- SOPH 144.5K
- CHRS 1.0M
- Earning Date
- SOPH 11-04-2025
- CHRS 11-06-2025
- Dividend Yield
- SOPH N/A
- CHRS N/A
- EPS Growth
- SOPH N/A
- CHRS N/A
- EPS
- SOPH N/A
- CHRS 1.55
- Revenue
- SOPH $73,297,000.00
- CHRS $272,209,000.00
- Revenue This Year
- SOPH $16.60
- CHRS N/A
- Revenue Next Year
- SOPH $19.09
- CHRS $109.48
- P/E Ratio
- SOPH N/A
- CHRS $1.01
- Revenue Growth
- SOPH 13.66
- CHRS 52.33
- 52 Week Low
- SOPH $2.58
- CHRS $0.66
- 52 Week High
- SOPH $5.30
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- SOPH 53.20
- CHRS 45.59
- Support Level
- SOPH $4.01
- CHRS $1.39
- Resistance Level
- SOPH $5.11
- CHRS $1.72
- Average True Range (ATR)
- SOPH 0.39
- CHRS 0.10
- MACD
- SOPH 0.02
- CHRS -0.03
- Stochastic Oscillator
- SOPH 49.68
- CHRS 40.70
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.